2020.09.05 2020.9-Biocentury: Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders
2020.09.04 2020.9-Endpoints: AbbVie jumps into CD47 game, engineers $3B deal with ambitious Chinese player
2020.09.04 AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
2020.08.31 I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
2020.08.17 I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
2020.08.06 I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020
2020.08.04 China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency